K-V Pharmaceutical (KV-a) Surges on FDA Guidance on Makena
Tweet
Share
E-mail
K-V Pharmaceutical (NYSE: KV-A) (NYSE: KV-B) is booming in pre-open trading Monday after the FDA provided further guidance about Makena.
According to the company, FDA provides further guidance to healthcare providers and pregnant women at high risk for recurrent preterm birth, recommending the use of FDA-approved Makena® rather than compounded drug formulations of hydroxyprogesterone caproate. The agency also describes its enforcement policy towards compounded formulations of hydroxyprogesterone caproate.
Shares of KV last traded at $0.84, up 48 percent.
According to the company, FDA provides further guidance to healthcare providers and pregnant women at high risk for recurrent preterm birth, recommending the use of FDA-approved Makena® rather than compounded drug formulations of hydroxyprogesterone caproate. The agency also describes its enforcement policy towards compounded formulations of hydroxyprogesterone caproate.
Shares of KV last traded at $0.84, up 48 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Harrow study shows Iheezo cuts discomfort after eye injections
- FDA grants accelerated approval to Ultragenyx gene therapy for GSDIa
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
